British American Tobacco p.l.c.: Anticipation of a bearish reversal
Published on 01/23/2015
at 09:03 am GMT
| Entry price | Target | Stop-loss | Potential |
|---|
|
GBX 3,767 |
GBX 3,554 |
GBX 3,914.75 |
+5.65% |
|---|
British American Tobacco should undergo some profit-taking after the rebound in recent sessions.
From a fundamental viewpoint, the company could suffer from downward EPS revisions from analysts. Indeed, this situation could lead the stock to more pronounce profit taking.
After a substantial upturn, the stock now approaches the resistance at GBp 3794.5, fact that could inverse the tendency. In addition, a high RSI indicator should entice a marked fall close to the short term GBp 3554 support. Moreover, in daily data, shares have just feed a double bottom pattern which could act as an additional argument for some profit taking.
The graphical configuration argues to establish a short position at the current price. The end of the technical rebound, the consolidation phase and overbought situation: British American Tobacco has all the characteristics for short selling. The first objective will be fixed near the GBp 3554 short term support. This strategy should be protected by a stop loss above GBp 3794.5.
© MarketScreener.com -
2015
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener UK. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.